UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Schedule 14F-1

Information Statement

Pursuant to Section 14(f) of the

Securities Exchange Act of 1934

and Rule 14f-1 Promulgated Thereunder

Trust Company Complex

Ajeltake Road

Majuro, Marshall Islands MH 96960

(Address of Principal Executive Offices and Zip Code)

(929) 314-3718

 (Registrant’s telephone number, including area code)

Date

May 16, 2017

ACCUREXA INC.

INFORMATION STATEMENT

(Pursuant to Section 14(f) of the Securities Exchange Act of 1934

and Rule 14f-1 thereunder)

THIS INFORMATION STATEMENT IS BEING PROVIDED FOR INFORMATIONAL PURPOSES ONLY. NO VOTE OR OTHER ACTION OF THE COMPANY’S STOCKHOLDERS IS REQUIRED IN CONNECTION WITH THIS INFORMATION STATEMENT. NO PROXIES ARE BEING SOLICITED AND YOU ARE REQUESTED NOT TO SEND A PROXY TO THE COMPANY.

INTRODUCTION

This Information Statement is being mailed on or about May 16, 2017, to holders of record at the close of business on May 16, 2017 (the “ Record Date ”), of shares of Common Stock, par value $0.0001 per share (the “ Common Stock ”), of ACCUREXA INC., a corporation organized under the laws of the Republic of the Marshall Islands (the “ Company ”), in connection with the change of control of and composition of the Board of Directors of the Company (the “ Board ”).   

The change of control is the result of the issuance of 10,000,000 shares of Common Stock of the Company to Medisun Holdings Limited, a Hong Kong entity (“Medisun”), representing approximately 51.6% of the issued and outstanding shares of Common Stock of the Company as of such date. The Company issued the foregoing shares to Medisun pursuant to a License Agreement between the Company and Medisun dated April 18, 2017, (the “ Closing Date ”), whereby Medisun granted Company a non-exclusive license to use its NK cell technology (and clinical network facilities in Greater China) for ten years.  The transactions described herein are more fully described in a certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on April 20, 2017 as amended.

This Information Statement is being furnished pursuant to Section 14(f) of the Securities Exchange Act of 1934 (the “ Exchange Act ”) and Rule 14f-1 thereunder. This Information Statement is being provided solely for informational purposes and not in connection with a vote of the Company’s security-holders.

No action is required by the Company’s stockholders in connection with this Information Statement.  Section 14(f) of the Exchange Act and Rule 14f-1 require the Company mail to its stockholders of record the information set forth in this Information Statement at least 10 days prior to the date a change in a majority of the Company’s directors occurs (otherwise than at a meeting of the Company’s stockholders). This Information Statement will be mailed to the Company’s stockholders of record on or about May 16, 2017.

CHANGE OF CONTROL

You are not required to vote on either the change of control or the addition of directors and your vote is not requested. Normally, the election of directors requires a vote of the holders of Common Stock entitled to vote.  In this case, the Company’s current directors appointed the new directors to the Board.  Therefore, no vote of stockholders of the Company is required to effectuate the appointment of the new directors.

On or about April 18, 2017 (the “ Closing Date ”), the Company issued to Medisun Holdings Limited 10,000,000 shares of its Common Stock, representing approximately 51.7% of the issued and outstanding shares of Common Stock of the Company as of such date.

In addition, on the Closing Date, Bryan Lee, Stefan Moll, and Oliver Jackson resigned their positions as executive officers and directors of the Company, effective immediately. The Company’s Board of Directors appointed Ms. Sophia Yaqi Sun as President, Chief Executive Officer, and Chief Financial Officer.  In addition, Lee, Moll, and Jackson resigned as members of the Board of Directors, which shall become effective on the 10 ^th day following the mailing of this information statement to the stockholders of the Company (the “Effective Date”).  On the Closing date, the Board appointed Ms. Sophia Yaqi Sun and Ms. Lisha Huang as directors, effective immediately.

DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

To the best of the Company’s knowledge, except as set forth below, the incoming directors have not been involved in any transactions with the Company or any of its directors, executive officers, affiliates or associates that are required to be disclosed pursuant to the rules and regulations of the SEC.  The names of the Company’s incoming officers and directors as of the Record Date, as well as certain information about them, are set forth below:

2

Distributions may be paid to the holders of our common stock if, as and when authorized by our board of directors and declared by us out of assets legally available therefor. Shares of our common stock have no preemptive, conversion or redemption rights and are freely transferable, except where their transfer is restricted by federal and state securities laws or by contract. In the event of our liquidation, dissolution or winding up, each share of our common stock would be entitled to a pro rata share of our assets that are legally available for distribution after we pay all debts and other liabilities and subject to any preferential rights of holders of our preferred stock, if any preferred stock is outstanding at such time. Each share of our common stock is entitled to one vote on an as converted basis on all matters submitted to a vote of stockholders, including the election of directors.

Preferred Stock

Our charter authorizes us to issue up to 2,000,000 shares of Preferred Stock, par value $0.0001. As of May 16, 2017, there were 1,625 shares of Preferred Stock outstanding.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding beneficial ownership of our voting stock as of May 16, 2017 (i) by each stockholder who has reported or is known by us to have beneficial ownership of more than five percent of our Common Stock; (ii) by each of our current directors and executive officers; and (iii) by all of our current directors and executive officers as a group. As of May 16, 2017, there are 19,398,954 shares of Common Stock issued and outstanding.

LEGAL PROCEEDINGS

To the Company’s knowledge, no director, officer or affiliate of the Company, and no owner of record or beneficial owner of more than five percent (5%) of the securities of the Company, or any associate of any such director, officer or security holder is a party adverse to the Company or has a material interest adverse to the Company in reference to pending litigation.

COMPENSATION OF DIRECTORS

The Company has not paid any compensation to its Board of Directors.  The Board, at its sole discretion, may vote to provide members of the Board either cash or equity consideration for their services.

NO STOCKHOLDER ACTION REQUIRED

This Information Statement is being provided for informational purposes only, and does not relate to any meeting of stockholders. Neither applicable securities laws, nor the corporate laws of the Republic of the Marshall Islands

4

require approval of the transaction referred to herein. No vote or other action is being requested of the Company’s stockholders. This Information Statement is provided for informational purposes only.

This Information Statement has been filed with the Securities and Exchange Commission and is available electronically on EDGAR at www.sec.gov .

SIGNATURE

            Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

5